3-[[(2R)-4-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-[[(2R)-4-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoic acid
• 化学式: C₃₁H₄₇NO₆
• 分子量: 529.7
• InChiKey: CETKYINPYJFIAZ-HTGXZGLSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  38
• 可旋转键数：
  22
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER METABOLIC DISEASES<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DE MALADIES MÉTABOLIQUES HÉPATIQUES
  申请人：MOHAN M ALAPATI

  公开号：WO2016046680A2

  公开（公告）日：2016-03-31

  The invention relates to the compositions of formula I, formula II, formula III, formula IV, formula V and formula VI or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of bile acid and the methods for treating or preventing liver diseases, fatty liver, NASH, metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of NASH, Fatty liver, liver cirrhosis and metabolic syndrome.